Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 05 - 11 entities : Eli lilly and company save search
FDA Approves Lilly and Incyte's Olumiant For Hospitalized COVID-19 Patients
Published: 2022-05-11 (Crawled : 16:00) - biospace.com/
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
covid-19 fda olumiant
FDA Approves Eli Lily's Olumiant For Hospitalized COVID-19 Patients
Published: 2022-05-11 (Crawled : 16:00) - biospace.com/
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
covid-19 fda olumiant covid
The PCSK9 Inhibitors Market to Grow Rapidly During the Forecast Period with a CAGR of 15.1%, Analyzes DelveInsight
Published: 2022-05-11 (Crawled : 15:00) - prnewswire.com
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.33%
H: 0.0%
C: 0.0%
market
Artax Biopharma Closes Financing to Advance Clinical Stage First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases
Published: 2022-05-11 (Crawled : 12:20) - prnewswire.com
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
biopharma disease
Heart Failure Treatment Offers Hope to Diabetics
Published: 2022-05-11 (Crawled : 12:00) - prnewswire.com
NVO | News | $126.16 -1.93% -2.24% 3M
|
Health Technology
|
| O: -2.55%
H: 2.32%
C: -0.85%
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.33%
H: 0.0%
C: 0.0%
treatment heart
FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19
Published: 2022-05-11 (Crawled : 11:00) - prnewswire.com
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
INCY | $51.74 0.17% 0.14% 1.6M
|
Health Technology
|
| O: 2.48%
H: 1.15%
C: -2.43%
covid-19 olumiant treatment fda
FDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 Patients
Published: 2022-05-11 (Crawled : 11:00) - biospace.com/
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: -3.03%
H: 0.0%
C: 0.0%
VERU | $1.32 3.53% 3.77% 1.5M
|
Health Technology
|
| O: 20.75%
H: 0.0%
C: 0.0%
covid-19 fda sabizabulin authorization positive phase 3 emergency use authorization
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.